nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprazolam—CYP3A5—Teniposide—lymphatic system cancer	0.151	0.214	CbGbCtD
Alprazolam—CYP2C9—Teniposide—lymphatic system cancer	0.101	0.143	CbGbCtD
Alprazolam—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.097	0.137	CbGbCtD
Alprazolam—CYP3A7—Vincristine—lymphatic system cancer	0.097	0.137	CbGbCtD
Alprazolam—CYP3A5—Vincristine—lymphatic system cancer	0.0727	0.103	CbGbCtD
Alprazolam—CYP3A4—Cytarabine—lymphatic system cancer	0.0598	0.0846	CbGbCtD
Alprazolam—CYP3A4—Teniposide—lymphatic system cancer	0.0589	0.0833	CbGbCtD
Alprazolam—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0412	0.0583	CbGbCtD
Alprazolam—CYP3A4—Vincristine—lymphatic system cancer	0.0284	0.0401	CbGbCtD
Alprazolam—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000915	0.00313	CcSEcCtD
Alprazolam—Sweating—Mitoxantrone—lymphatic system cancer	0.000913	0.00312	CcSEcCtD
Alprazolam—Dyspnoea—Fludarabine—lymphatic system cancer	0.00091	0.00311	CcSEcCtD
Alprazolam—Oedema peripheral—Carmustine—lymphatic system cancer	0.000906	0.0031	CcSEcCtD
Alprazolam—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000904	0.00309	CcSEcCtD
Alprazolam—Dyspepsia—Fludarabine—lymphatic system cancer	0.000899	0.00307	CcSEcCtD
Alprazolam—Dysarthria—Methotrexate—lymphatic system cancer	0.000897	0.00307	CcSEcCtD
Alprazolam—Decreased appetite—Fludarabine—lymphatic system cancer	0.000888	0.00303	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000881	0.00301	CcSEcCtD
Alprazolam—Fatigue—Fludarabine—lymphatic system cancer	0.00088	0.00301	CcSEcCtD
Alprazolam—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000874	0.00299	CcSEcCtD
Alprazolam—Hallucination—Vincristine—lymphatic system cancer	0.000874	0.00299	CcSEcCtD
Alprazolam—Constipation—Fludarabine—lymphatic system cancer	0.000873	0.00298	CcSEcCtD
Alprazolam—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000867	0.00296	CcSEcCtD
Alprazolam—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000863	0.00295	CcSEcCtD
Alprazolam—Urethral disorder—Vincristine—lymphatic system cancer	0.000861	0.00294	CcSEcCtD
Alprazolam—Eye disorder—Carmustine—lymphatic system cancer	0.00086	0.00294	CcSEcCtD
Alprazolam—Hypersensitivity—Teniposide—lymphatic system cancer	0.000856	0.00293	CcSEcCtD
Alprazolam—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000855	0.00292	CcSEcCtD
Alprazolam—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000851	0.00291	CcSEcCtD
Alprazolam—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000841	0.00288	CcSEcCtD
Alprazolam—Asthenia—Teniposide—lymphatic system cancer	0.000833	0.00285	CcSEcCtD
Alprazolam—Malaise—Bleomycin—lymphatic system cancer	0.000827	0.00283	CcSEcCtD
Alprazolam—Pruritus—Teniposide—lymphatic system cancer	0.000822	0.00281	CcSEcCtD
Alprazolam—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000819	0.0028	CcSEcCtD
Alprazolam—Cardiac disorder—Vincristine—lymphatic system cancer	0.000815	0.00279	CcSEcCtD
Alprazolam—Body temperature increased—Fludarabine—lymphatic system cancer	0.000807	0.00276	CcSEcCtD
Alprazolam—Mental disorder—Carmustine—lymphatic system cancer	0.000806	0.00275	CcSEcCtD
Alprazolam—Malnutrition—Carmustine—lymphatic system cancer	0.000801	0.00274	CcSEcCtD
Alprazolam—Angiopathy—Vincristine—lymphatic system cancer	0.000797	0.00272	CcSEcCtD
Alprazolam—Diarrhoea—Teniposide—lymphatic system cancer	0.000795	0.00272	CcSEcCtD
Alprazolam—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000791	0.00271	CcSEcCtD
Alprazolam—Chest pain—Bleomycin—lymphatic system cancer	0.000781	0.00267	CcSEcCtD
Alprazolam—Myalgia—Bleomycin—lymphatic system cancer	0.000781	0.00267	CcSEcCtD
Alprazolam—Back pain—Carmustine—lymphatic system cancer	0.000774	0.00265	CcSEcCtD
Alprazolam—Discomfort—Bleomycin—lymphatic system cancer	0.000772	0.00264	CcSEcCtD
Alprazolam—Mental disorder—Vincristine—lymphatic system cancer	0.000769	0.00263	CcSEcCtD
Alprazolam—Chills—Mitoxantrone—lymphatic system cancer	0.000767	0.00262	CcSEcCtD
Alprazolam—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000759	0.00259	CcSEcCtD
Alprazolam—Confusional state—Bleomycin—lymphatic system cancer	0.000755	0.00258	CcSEcCtD
Alprazolam—Vision blurred—Carmustine—lymphatic system cancer	0.000755	0.00258	CcSEcCtD
Alprazolam—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000752	0.00257	CcSEcCtD
Alprazolam—Tremor—Carmustine—lymphatic system cancer	0.00075	0.00256	CcSEcCtD
Alprazolam—Oedema—Bleomycin—lymphatic system cancer	0.000749	0.00256	CcSEcCtD
Alprazolam—Infection—Bleomycin—lymphatic system cancer	0.000744	0.00254	CcSEcCtD
Alprazolam—Back pain—Vincristine—lymphatic system cancer	0.000739	0.00253	CcSEcCtD
Alprazolam—Vomiting—Teniposide—lymphatic system cancer	0.000739	0.00253	CcSEcCtD
Alprazolam—Agitation—Carmustine—lymphatic system cancer	0.000736	0.00252	CcSEcCtD
Alprazolam—Asthenia—Fludarabine—lymphatic system cancer	0.000733	0.0025	CcSEcCtD
Alprazolam—Rash—Teniposide—lymphatic system cancer	0.000732	0.0025	CcSEcCtD
Alprazolam—Dermatitis—Teniposide—lymphatic system cancer	0.000732	0.0025	CcSEcCtD
Alprazolam—Headache—Teniposide—lymphatic system cancer	0.000728	0.00249	CcSEcCtD
Alprazolam—Pruritus—Fludarabine—lymphatic system cancer	0.000722	0.00247	CcSEcCtD
Alprazolam—Back pain—Mitoxantrone—lymphatic system cancer	0.00072	0.00246	CcSEcCtD
Alprazolam—Anorexia—Bleomycin—lymphatic system cancer	0.000714	0.00244	CcSEcCtD
Alprazolam—Agitation—Vincristine—lymphatic system cancer	0.000702	0.0024	CcSEcCtD
Alprazolam—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000701	0.0024	CcSEcCtD
Alprazolam—Hypotension—Bleomycin—lymphatic system cancer	0.000699	0.00239	CcSEcCtD
Alprazolam—Diarrhoea—Fludarabine—lymphatic system cancer	0.000699	0.00239	CcSEcCtD
Alprazolam—Convulsion—Carmustine—lymphatic system cancer	0.000694	0.00237	CcSEcCtD
Alprazolam—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000691	0.00236	CcSEcCtD
Alprazolam—Nausea—Teniposide—lymphatic system cancer	0.00069	0.00236	CcSEcCtD
Alprazolam—Vertigo—Vincristine—lymphatic system cancer	0.000687	0.00235	CcSEcCtD
Alprazolam—Hepatic failure—Methotrexate—lymphatic system cancer	0.000685	0.00234	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000682	0.00233	CcSEcCtD
Alprazolam—Chest pain—Carmustine—lymphatic system cancer	0.000682	0.00233	CcSEcCtD
Alprazolam—Myalgia—Carmustine—lymphatic system cancer	0.000682	0.00233	CcSEcCtD
Alprazolam—Anxiety—Carmustine—lymphatic system cancer	0.000679	0.00232	CcSEcCtD
Alprazolam—Paraesthesia—Bleomycin—lymphatic system cancer	0.000672	0.0023	CcSEcCtD
Alprazolam—Malaise—Mitoxantrone—lymphatic system cancer	0.000671	0.00229	CcSEcCtD
Alprazolam—Dyspnoea—Bleomycin—lymphatic system cancer	0.000667	0.00228	CcSEcCtD
Alprazolam—Convulsion—Vincristine—lymphatic system cancer	0.000662	0.00226	CcSEcCtD
Alprazolam—Confusional state—Carmustine—lymphatic system cancer	0.000659	0.00225	CcSEcCtD
Alprazolam—Oedema—Carmustine—lymphatic system cancer	0.000653	0.00223	CcSEcCtD
Alprazolam—Decreased appetite—Bleomycin—lymphatic system cancer	0.000651	0.00222	CcSEcCtD
Alprazolam—Myalgia—Vincristine—lymphatic system cancer	0.000651	0.00222	CcSEcCtD
Alprazolam—Infection—Carmustine—lymphatic system cancer	0.000649	0.00222	CcSEcCtD
Alprazolam—Vomiting—Fludarabine—lymphatic system cancer	0.000649	0.00222	CcSEcCtD
Alprazolam—Convulsion—Mitoxantrone—lymphatic system cancer	0.000645	0.0022	CcSEcCtD
Alprazolam—Rash—Fludarabine—lymphatic system cancer	0.000644	0.0022	CcSEcCtD
Alprazolam—Dermatitis—Fludarabine—lymphatic system cancer	0.000643	0.0022	CcSEcCtD
Alprazolam—Headache—Fludarabine—lymphatic system cancer	0.00064	0.00219	CcSEcCtD
Alprazolam—Tachycardia—Carmustine—lymphatic system cancer	0.000638	0.00218	CcSEcCtD
Alprazolam—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000634	0.00217	CcSEcCtD
Alprazolam—Myalgia—Mitoxantrone—lymphatic system cancer	0.000634	0.00217	CcSEcCtD
Alprazolam—Chest pain—Mitoxantrone—lymphatic system cancer	0.000634	0.00217	CcSEcCtD
Alprazolam—Anxiety—Mitoxantrone—lymphatic system cancer	0.000632	0.00216	CcSEcCtD
Alprazolam—Lethargy—Methotrexate—lymphatic system cancer	0.000628	0.00215	CcSEcCtD
Alprazolam—Discomfort—Mitoxantrone—lymphatic system cancer	0.000626	0.00214	CcSEcCtD
Alprazolam—Oedema—Vincristine—lymphatic system cancer	0.000624	0.00213	CcSEcCtD
Alprazolam—Anorexia—Carmustine—lymphatic system cancer	0.000623	0.00213	CcSEcCtD
Alprazolam—Infection—Vincristine—lymphatic system cancer	0.00062	0.00212	CcSEcCtD
Alprazolam—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000617	0.00211	CcSEcCtD
Alprazolam—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000616	0.00211	CcSEcCtD
Alprazolam—Confusional state—Mitoxantrone—lymphatic system cancer	0.000613	0.00209	CcSEcCtD
Alprazolam—Nervous system disorder—Vincristine—lymphatic system cancer	0.000612	0.00209	CcSEcCtD
Alprazolam—Hypotension—Carmustine—lymphatic system cancer	0.000611	0.00209	CcSEcCtD
Alprazolam—Oedema—Mitoxantrone—lymphatic system cancer	0.000607	0.00208	CcSEcCtD
Alprazolam—Nausea—Fludarabine—lymphatic system cancer	0.000606	0.00207	CcSEcCtD
Alprazolam—Infection—Mitoxantrone—lymphatic system cancer	0.000604	0.00206	CcSEcCtD
Alprazolam—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000603	0.00206	CcSEcCtD
Alprazolam—Shock—Mitoxantrone—lymphatic system cancer	0.000598	0.00204	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000595	0.00204	CcSEcCtD
Alprazolam—Urticaria—Bleomycin—lymphatic system cancer	0.000595	0.00203	CcSEcCtD
Alprazolam—Anorexia—Vincristine—lymphatic system cancer	0.000595	0.00203	CcSEcCtD
Alprazolam—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000593	0.00203	CcSEcCtD
Alprazolam—Body temperature increased—Bleomycin—lymphatic system cancer	0.000592	0.00202	CcSEcCtD
Alprazolam—Insomnia—Carmustine—lymphatic system cancer	0.000591	0.00202	CcSEcCtD
Alprazolam—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00059	0.00202	CcSEcCtD
Alprazolam—Irritability—Methotrexate—lymphatic system cancer	0.000588	0.00201	CcSEcCtD
Alprazolam—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000587	0.00201	CcSEcCtD
Alprazolam—Paraesthesia—Carmustine—lymphatic system cancer	0.000587	0.00201	CcSEcCtD
Alprazolam—Mood swings—Methotrexate—lymphatic system cancer	0.000583	0.00199	CcSEcCtD
Alprazolam—Hypotension—Vincristine—lymphatic system cancer	0.000583	0.00199	CcSEcCtD
Alprazolam—Dyspnoea—Carmustine—lymphatic system cancer	0.000583	0.00199	CcSEcCtD
Alprazolam—Somnolence—Carmustine—lymphatic system cancer	0.000581	0.00199	CcSEcCtD
Alprazolam—Anorexia—Mitoxantrone—lymphatic system cancer	0.000579	0.00198	CcSEcCtD
Alprazolam—Ataxia—Methotrexate—lymphatic system cancer	0.000579	0.00198	CcSEcCtD
Alprazolam—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000569	0.00194	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000568	0.00194	CcSEcCtD
Alprazolam—Decreased appetite—Carmustine—lymphatic system cancer	0.000568	0.00194	CcSEcCtD
Alprazolam—Hypotension—Mitoxantrone—lymphatic system cancer	0.000568	0.00194	CcSEcCtD
Alprazolam—Insomnia—Vincristine—lymphatic system cancer	0.000564	0.00193	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000564	0.00193	CcSEcCtD
Alprazolam—Paraesthesia—Vincristine—lymphatic system cancer	0.00056	0.00191	CcSEcCtD
Alprazolam—Constipation—Carmustine—lymphatic system cancer	0.000559	0.00191	CcSEcCtD
Alprazolam—Breast disorder—Methotrexate—lymphatic system cancer	0.000556	0.0019	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000553	0.00189	CcSEcCtD
Alprazolam—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000552	0.00189	CcSEcCtD
Alprazolam—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000545	0.00186	CcSEcCtD
Alprazolam—Decreased appetite—Vincristine—lymphatic system cancer	0.000542	0.00185	CcSEcCtD
Alprazolam—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000542	0.00185	CcSEcCtD
Alprazolam—Somnolence—Mitoxantrone—lymphatic system cancer	0.00054	0.00185	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000539	0.00184	CcSEcCtD
Alprazolam—Feeling abnormal—Carmustine—lymphatic system cancer	0.000538	0.00184	CcSEcCtD
Alprazolam—Fatigue—Vincristine—lymphatic system cancer	0.000538	0.00184	CcSEcCtD
Alprazolam—Asthenia—Bleomycin—lymphatic system cancer	0.000537	0.00184	CcSEcCtD
Alprazolam—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000535	0.00183	CcSEcCtD
Alprazolam—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000534	0.00183	CcSEcCtD
Alprazolam—Constipation—Vincristine—lymphatic system cancer	0.000533	0.00182	CcSEcCtD
Alprazolam—Pruritus—Bleomycin—lymphatic system cancer	0.00053	0.00181	CcSEcCtD
Alprazolam—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000528	0.00181	CcSEcCtD
Alprazolam—Fatigue—Mitoxantrone—lymphatic system cancer	0.000524	0.00179	CcSEcCtD
Alprazolam—Constipation—Mitoxantrone—lymphatic system cancer	0.000519	0.00178	CcSEcCtD
Alprazolam—Abdominal pain—Carmustine—lymphatic system cancer	0.000517	0.00177	CcSEcCtD
Alprazolam—Body temperature increased—Carmustine—lymphatic system cancer	0.000517	0.00177	CcSEcCtD
Alprazolam—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00051	0.00174	CcSEcCtD
Alprazolam—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00051	0.00174	CcSEcCtD
Alprazolam—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000501	0.00171	CcSEcCtD
Alprazolam—Dysuria—Methotrexate—lymphatic system cancer	0.000498	0.0017	CcSEcCtD
Alprazolam—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000497	0.0017	CcSEcCtD
Alprazolam—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000495	0.00169	CcSEcCtD
Alprazolam—Abdominal pain—Vincristine—lymphatic system cancer	0.000493	0.00169	CcSEcCtD
Alprazolam—Body temperature increased—Vincristine—lymphatic system cancer	0.000493	0.00169	CcSEcCtD
Alprazolam—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000486	0.00166	CcSEcCtD
Alprazolam—Urticaria—Mitoxantrone—lymphatic system cancer	0.000483	0.00165	CcSEcCtD
Alprazolam—Hypersensitivity—Carmustine—lymphatic system cancer	0.000481	0.00165	CcSEcCtD
Alprazolam—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00048	0.00164	CcSEcCtD
Alprazolam—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00048	0.00164	CcSEcCtD
Alprazolam—Vomiting—Bleomycin—lymphatic system cancer	0.000476	0.00163	CcSEcCtD
Alprazolam—Infestation NOS—Methotrexate—lymphatic system cancer	0.000475	0.00162	CcSEcCtD
Alprazolam—Infestation—Methotrexate—lymphatic system cancer	0.000475	0.00162	CcSEcCtD
Alprazolam—Drowsiness—Methotrexate—lymphatic system cancer	0.000475	0.00162	CcSEcCtD
Alprazolam—Depression—Methotrexate—lymphatic system cancer	0.000473	0.00162	CcSEcCtD
Alprazolam—Rash—Bleomycin—lymphatic system cancer	0.000472	0.00161	CcSEcCtD
Alprazolam—Dermatitis—Bleomycin—lymphatic system cancer	0.000472	0.00161	CcSEcCtD
Alprazolam—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00047	0.00161	CcSEcCtD
Alprazolam—Asthenia—Carmustine—lymphatic system cancer	0.000469	0.0016	CcSEcCtD
Alprazolam—Hypersensitivity—Vincristine—lymphatic system cancer	0.00046	0.00157	CcSEcCtD
Alprazolam—Sweating—Methotrexate—lymphatic system cancer	0.000455	0.00156	CcSEcCtD
Alprazolam—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000449	0.00153	CcSEcCtD
Alprazolam—Epistaxis—Methotrexate—lymphatic system cancer	0.000448	0.00153	CcSEcCtD
Alprazolam—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000448	0.00153	CcSEcCtD
Alprazolam—Asthenia—Vincristine—lymphatic system cancer	0.000448	0.00153	CcSEcCtD
Alprazolam—Diarrhoea—Carmustine—lymphatic system cancer	0.000447	0.00153	CcSEcCtD
Alprazolam—Nausea—Bleomycin—lymphatic system cancer	0.000445	0.00152	CcSEcCtD
Alprazolam—Asthenia—Mitoxantrone—lymphatic system cancer	0.000436	0.00149	CcSEcCtD
Alprazolam—Dizziness—Carmustine—lymphatic system cancer	0.000432	0.00148	CcSEcCtD
Alprazolam—Diarrhoea—Vincristine—lymphatic system cancer	0.000427	0.00146	CcSEcCtD
Alprazolam—Hepatitis—Methotrexate—lymphatic system cancer	0.000426	0.00146	CcSEcCtD
Alprazolam—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000421	0.00144	CcSEcCtD
Alprazolam—Urethral disorder—Methotrexate—lymphatic system cancer	0.000418	0.00143	CcSEcCtD
Alprazolam—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000416	0.00142	CcSEcCtD
Alprazolam—Vomiting—Carmustine—lymphatic system cancer	0.000415	0.00142	CcSEcCtD
Alprazolam—Dizziness—Vincristine—lymphatic system cancer	0.000412	0.00141	CcSEcCtD
Alprazolam—Rash—Carmustine—lymphatic system cancer	0.000412	0.00141	CcSEcCtD
Alprazolam—Dermatitis—Carmustine—lymphatic system cancer	0.000412	0.00141	CcSEcCtD
Alprazolam—Headache—Carmustine—lymphatic system cancer	0.000409	0.0014	CcSEcCtD
Alprazolam—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000403	0.00138	CcSEcCtD
Alprazolam—Eye disorder—Methotrexate—lymphatic system cancer	0.000398	0.00136	CcSEcCtD
Alprazolam—Tinnitus—Methotrexate—lymphatic system cancer	0.000397	0.00136	CcSEcCtD
Alprazolam—Vomiting—Vincristine—lymphatic system cancer	0.000397	0.00136	CcSEcCtD
Alprazolam—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000395	0.00135	CcSEcCtD
Alprazolam—Rash—Vincristine—lymphatic system cancer	0.000393	0.00134	CcSEcCtD
Alprazolam—Dermatitis—Vincristine—lymphatic system cancer	0.000393	0.00134	CcSEcCtD
Alprazolam—Headache—Vincristine—lymphatic system cancer	0.000391	0.00134	CcSEcCtD
Alprazolam—Nausea—Carmustine—lymphatic system cancer	0.000388	0.00133	CcSEcCtD
Alprazolam—Angiopathy—Methotrexate—lymphatic system cancer	0.000387	0.00132	CcSEcCtD
Alprazolam—Vomiting—Mitoxantrone—lymphatic system cancer	0.000386	0.00132	CcSEcCtD
Alprazolam—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000384	0.00131	CcSEcCtD
Alprazolam—Rash—Mitoxantrone—lymphatic system cancer	0.000383	0.00131	CcSEcCtD
Alprazolam—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000383	0.00131	CcSEcCtD
Alprazolam—Chills—Methotrexate—lymphatic system cancer	0.000382	0.00131	CcSEcCtD
Alprazolam—Headache—Mitoxantrone—lymphatic system cancer	0.000381	0.0013	CcSEcCtD
Alprazolam—Mental disorder—Methotrexate—lymphatic system cancer	0.000373	0.00128	CcSEcCtD
Alprazolam—Malnutrition—Methotrexate—lymphatic system cancer	0.000371	0.00127	CcSEcCtD
Alprazolam—Nausea—Vincristine—lymphatic system cancer	0.000371	0.00127	CcSEcCtD
Alprazolam—Nausea—Mitoxantrone—lymphatic system cancer	0.000361	0.00123	CcSEcCtD
Alprazolam—Back pain—Methotrexate—lymphatic system cancer	0.000359	0.00123	CcSEcCtD
Alprazolam—Vision blurred—Methotrexate—lymphatic system cancer	0.00035	0.00119	CcSEcCtD
Alprazolam—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000344	0.00118	CcSEcCtD
Alprazolam—Malaise—Methotrexate—lymphatic system cancer	0.000334	0.00114	CcSEcCtD
Alprazolam—Vertigo—Methotrexate—lymphatic system cancer	0.000333	0.00114	CcSEcCtD
Alprazolam—Convulsion—Methotrexate—lymphatic system cancer	0.000321	0.0011	CcSEcCtD
Alprazolam—Arthralgia—Methotrexate—lymphatic system cancer	0.000316	0.00108	CcSEcCtD
Alprazolam—Myalgia—Methotrexate—lymphatic system cancer	0.000316	0.00108	CcSEcCtD
Alprazolam—Chest pain—Methotrexate—lymphatic system cancer	0.000316	0.00108	CcSEcCtD
Alprazolam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000314	0.00107	CcSEcCtD
Alprazolam—Discomfort—Methotrexate—lymphatic system cancer	0.000312	0.00107	CcSEcCtD
Alprazolam—Confusional state—Methotrexate—lymphatic system cancer	0.000305	0.00104	CcSEcCtD
Alprazolam—Infection—Methotrexate—lymphatic system cancer	0.000301	0.00103	CcSEcCtD
Alprazolam—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000297	0.00101	CcSEcCtD
Alprazolam—Skin disorder—Methotrexate—lymphatic system cancer	0.000294	0.00101	CcSEcCtD
Alprazolam—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000293	0.001	CcSEcCtD
Alprazolam—Anorexia—Methotrexate—lymphatic system cancer	0.000289	0.000986	CcSEcCtD
Alprazolam—Hypotension—Methotrexate—lymphatic system cancer	0.000283	0.000967	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000276	0.000943	CcSEcCtD
Alprazolam—Insomnia—Methotrexate—lymphatic system cancer	0.000274	0.000936	CcSEcCtD
Alprazolam—Paraesthesia—Methotrexate—lymphatic system cancer	0.000272	0.000929	CcSEcCtD
Alprazolam—Dyspnoea—Methotrexate—lymphatic system cancer	0.00027	0.000923	CcSEcCtD
Alprazolam—Somnolence—Methotrexate—lymphatic system cancer	0.000269	0.00092	CcSEcCtD
Alprazolam—Dyspepsia—Methotrexate—lymphatic system cancer	0.000266	0.000911	CcSEcCtD
Alprazolam—Decreased appetite—Methotrexate—lymphatic system cancer	0.000263	0.0009	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000261	0.000893	CcSEcCtD
Alprazolam—Fatigue—Methotrexate—lymphatic system cancer	0.000261	0.000892	CcSEcCtD
Alprazolam—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000249	0.000853	CcSEcCtD
Alprazolam—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000247	0.000846	CcSEcCtD
Alprazolam—Urticaria—Methotrexate—lymphatic system cancer	0.00024	0.000822	CcSEcCtD
Alprazolam—Abdominal pain—Methotrexate—lymphatic system cancer	0.000239	0.000818	CcSEcCtD
Alprazolam—Body temperature increased—Methotrexate—lymphatic system cancer	0.000239	0.000818	CcSEcCtD
Alprazolam—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000223	0.000762	CcSEcCtD
Alprazolam—Asthenia—Methotrexate—lymphatic system cancer	0.000217	0.000742	CcSEcCtD
Alprazolam—Pruritus—Methotrexate—lymphatic system cancer	0.000214	0.000732	CcSEcCtD
Alprazolam—Diarrhoea—Methotrexate—lymphatic system cancer	0.000207	0.000708	CcSEcCtD
Alprazolam—Dizziness—Methotrexate—lymphatic system cancer	0.0002	0.000684	CcSEcCtD
Alprazolam—Vomiting—Methotrexate—lymphatic system cancer	0.000192	0.000658	CcSEcCtD
Alprazolam—Rash—Methotrexate—lymphatic system cancer	0.000191	0.000652	CcSEcCtD
Alprazolam—Dermatitis—Methotrexate—lymphatic system cancer	0.000191	0.000652	CcSEcCtD
Alprazolam—Headache—Methotrexate—lymphatic system cancer	0.00019	0.000648	CcSEcCtD
Alprazolam—Nausea—Methotrexate—lymphatic system cancer	0.00018	0.000615	CcSEcCtD
